Velarion · Company Intelligence
Compensation Brief
Fiscal year 2025 · Filings through 2026-07-29

Atea Pharmaceuticals, Inc. (AVIR)

CEO Jean-Pierre Sommadossi was paid $3,403,752 in fiscal year 2025, ↓ down 19.0% from fiscal year 2024, the 59th percentile of its disclosed peer group (SEC filing 0001193125-26-182293 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$3,403,752 ↓
Jean-Pierre Sommadossi total, FY2025
59th
CEO pay percentile vs peers
—
CEO-to-median pay ratio
94.1%
Say-on-pay support, latest vote

Track this company's pay every filing: join the Pro seat waitlist

Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year

A confirmation now and one email when Pro opens, and nothing else. Privacy

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Jean-Pierre Sommadossi (President, Chief Executive Officer and Chairman of the Board), FY2025 total compensation $3,403,752 (base salary $703,490) [exec_comp, SEC accession 0001193125-26-182293, filed 2026-04-27]

Answered within 24 hours, every figure cited to its SEC filing. If our database cannot answer your question, you are refunded automatically.

AVIR's next annual pay disclosure, estimated April 27, 2027.est. Filing ↗

01

Summary Compensation Table — fiscal year 2025

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Jean-Pierre Sommadossi$703,490$0$1,315,800$962,368$422,094$0$0$3,403,752
President, Chief Executive Officer and Chairman of the Board
Janet Hammond590,8920459,000437,440265,902014,0001,767,234
Chief Development Officer
Andrea Corcoran549,5300442,170437,440247,288014,0001,690,428
Chief Financial Officer, Executive Vice President, Legal
Maria Arantxa Horga523,6440425,034421,692209,458014,0001,593,827
Chief Medical Officer
John Vavricka443,1690292,842290,460177,268014,0001,217,738
Chief Commercial Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2025 totalFY2024 totalFY2023 totalΔ FY2024→2025
Jean-Pierre Sommadossi$3,403,752$4,202,323$5,925,790↓ −798,571
Janet Hammond1,767,2342,159,0312,107,297↓ −391,797
Andrea Corcoran1,690,4281,931,8321,961,524↓ −241,404
Maria Arantxa Horga1,593,8271,853,3061,849,189↓ −259,479
John Vavricka1,217,7381,386,6631,515,658↓ −168,925

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

You have just read Atea Pharmaceuticals, Inc.'s Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper AVIR reports.

We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.

Get the Atea Pharmaceuticals, Inc. Peer Teardown Report

$3,403,752 Jean-Pierre Sommadossi total, FY2025

$199

The free page is the headline. The teardown reads every company in the disclosed peer group on its own numbers.

Data as of July 29, 2026 · Source: 0001193125-26-182293 · Velarion Executive Compensation Database, deposited on Zenodo (doi:10.5281/zenodo.22283855).

Reports for AVIR

Every report below is generated from the same filings as the free brief above, at the moment of purchase. What each one adds:

Executive Compensation ReportThe free page is the headline figures. The report is every award, peer and vote combined into one document you can hand to a committee.$1,500 →Reverse Peer AnalysisThe free page is the one line. The analysis reads every company that names this one in its own peer group.$299 →Peer Teardown ReportThe free page is the headline. The teardown reads every company in the disclosed peer group on its own numbers.$199 →
AVIRon Velarion Intel, free → The platform reading of this company, beside the same data as a subscription.

Order AVIR

Pick the report, add the email the receipt and the PDF go to, and pay by card on Stripe.

Receipt, invoice, and report delivery. Guest checkout, no account required, secure payment by Stripe.

How we handle your data → Privacy

Companies that benchmark against AVIR
4 companies name AVIR as a compensation peer

Each company listed discloses AVIR in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named AVIR in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.

Get the Atea Pharmaceuticals, Inc. Executive Compensation Report

$1,500

Buy the report - $1,500Both reports - $2,400
01c

Board of directors

One page per director: the seat, the committees and the fee table, read for one person at a time.

DirectorRoleFY2025 total
Arthur KirschIndependent Director$415,333
Barbara DuncanIndependent Director$256,902
Bruno LucidiIndependent Director$249,402
Franklin BergerIndependent Director$282,902
Howard BermanIndependent Director$407,114
02

Equity transactions since the proxy statement was filed

Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Polly MurphyDirector2026-05-18A6,100$4$25,446CommonForm 4 ↗
Howard BermanDirector2026-06-18A26,70000Derivative, Class A CommonForm 4 ↗
Bruno LucidiDirector2026-06-18A29,60000CommonForm 4 ↗
Arthur KirschDirector2026-06-18A37,70000Derivative, Class A CommonForm 4 ↗
Arthur KirschDirector2026-06-18A26,70000Derivative, Class A CommonForm 4 ↗
Jerome AdamsDirector2026-06-18A37,70000Derivative, Class A CommonForm 4 ↗
Jerome AdamsDirector2026-06-18A26,70000Derivative, Class A CommonForm 4 ↗
Jerome AdamsDirector2026-06-18D29,60000Derivative, Class A CommonForm 4 ↗
Jerome AdamsDirector2026-06-18A29,60000CommonForm 4 ↗
Polly MurphyDirector2026-06-18A37,70000Derivative, Class A CommonForm 4 ↗
Polly MurphyDirector2026-06-18A26,70000Derivative, Class A CommonForm 4 ↗
Polly MurphyDirector2026-06-18D29,60000Derivative, Class A CommonForm 4 ↗
Polly MurphyDirector2026-06-18A29,60000CommonForm 4 ↗
Bruce PolskyDirector2026-06-18A26,70000Derivative, Class A CommonForm 4 ↗
Bruce PolskyDirector2026-06-18D29,60000Derivative, Class A CommonForm 4 ↗
Bruce PolskyDirector2026-06-18A29,60000CommonForm 4 ↗
Barbara DuncanDirector2026-06-18A37,70000Derivative, Class A CommonForm 4 ↗
Barbara DuncanDirector2026-06-18A26,70000Derivative, Class A CommonForm 4 ↗
Barbara DuncanDirector2026-06-18D29,60000Derivative, Class A CommonForm 4 ↗
Barbara DuncanDirector2026-06-18A29,60000CommonForm 4 ↗
Howard BermanDirector2026-06-18A37,70000Derivative, Class A CommonForm 4 ↗
Franklin BergerDirector2026-06-18A37,70000Derivative, Class A CommonForm 4 ↗
Franklin BergerDirector2026-06-18D29,60000Derivative, Class A CommonForm 4 ↗
Franklin BergerDirector2026-06-18A29,60000CommonForm 4 ↗
Bruno LucidiDirector2026-06-18A37,70000Derivative, Class A CommonForm 4 ↗
Bruno LucidiDirector2026-06-18A26,70000Derivative, Class A CommonForm 4 ↗
Bruno LucidiDirector2026-06-18D29,60000Derivative, Class A CommonForm 4 ↗
Bruce PolskyDirector2026-06-18A37,70000Derivative, Class A CommonForm 4 ↗
Franklin BergerDirector2026-06-18A26,70000Derivative, Class A CommonForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

03

Grants of plan-based awards — fiscal year 2025

ExecutiveAwardGrant dateThresholdTargetGrantedMaximumGrant-date fair value
Janet HammondPSU2025-01-3175,000150,000—300,000$459,000
John VavrickaOPTION2025-01-31——132,800—290,460
Andrea CorcoranOPTION2025-01-31——200,000—437,440
Jean-Pierre SommadossiPSU2025-01-31215,000430,000—860,0001,315,800
John VavrickaPSU2025-01-3147,85095,700—191,400292,842
Jean-Pierre SommadossiOPTION2025-01-31——440,000—962,368
Andrea CorcoranPSU2025-01-3172,250144,500—289,000442,170
Janet HammondOPTION2025-01-31——200,000—437,440
Maria Arantxa HorgaPSU2025-01-3169,450138,900—277,800425,034
Maria Arantxa HorgaOPTION2025-01-31——192,800—421,692
03b

Vehicle mix — grant-date fair value by award type

Named executive officerTime-vested (RSU)Performance-vested (PSU)Options / SARs% performance-vested
Janet Hammond$0$459,000$437,44051.2%
John Vavricka0292,842290,46050.2%
Andrea Corcoran0442,170437,44050.3%
Jean-Pierre Sommadossi01,315,800962,36857.8%
Maria Arantxa Horga0425,034421,69250.2%

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

04

Outstanding equity awards at fiscal year-end 2025

ExecutiveAwardShares unvestedExercise priceMarket value unvested
Andrea CorcoranPSU72,250—$257,933
John VavrickaRSU33,333—118,999
John VavrickaPSU95,700—341,649
Janet HammondOption154,1673.06—
John VavrickaOption37,9174.63—
Andrea CorcoranRSU44,366—158,387
Jean-Pierre SommadossiPSU430,000—1,535,100
Andrea CorcoranRSU10,500—37,485
Jean-Pierre SommadossiPSU215,000—767,550
Jean-Pierre SommadossiRSU173,466—619,274
Janet HammondPSU162,300—579,411
Andrea CorcoranPSU144,500—515,865
John VavrickaOption69,1674.16—
Maria Arantxa HorgaPSU138,900—495,873
Jean-Pierre SommadossiRSU99,517—355,274
Janet HammondPSU75,000—267,750
Maria Arantxa HorgaPSU69,450—247,937
John VavrickaPSU47,850—170,825
Janet HammondRSU46,800—167,076
Maria Arantxa HorgaRSU41,533—148,273
Janet HammondRSU11,250—40,163
Maria Arantxa HorgaRSU9,750—34,808
John VavrickaRSU8,750—31,238
Maria Arantxa HorgaOption100,4174.16—
Jean-Pierre SommadossiOption233,3344.16—
Jean-Pierre SommadossiOption197,3304.63—
Jean-Pierre SommadossiOption7,8767.14—
Andrea CorcoranOption154,1673.06—
Andrea CorcoranOption104,1674.16—
Andrea CorcoranOption50,4574.63—
Andrea CorcoranOption3,7717.14—
Janet HammondOption117,2924.16—
Janet HammondOption53,2464.63—
Janet HammondOption3,9597.14—
Maria Arantxa HorgaOption148,6173.06—
Maria Arantxa HorgaOption47,2614.63—
Maria Arantxa HorgaOption3,5427.14—
John VavrickaOption102,3673.06—
John VavrickaOption2,8137.14—
05

Incentive-plan design — the Compensation Discussion & Analysis

Our Executive Compensation Philosophy is designed to reward executives for actions that create incremental stockholder value and align the interests of stockholders and executives. We emphasize at-risk compensation, balance short- and long-term incentives, and focus on equity pay mix to ensure executives' interests are aligned with long-term stockholders.

CEO STI target (% of salary)—
CEO LTI target (% of salary)—
Independent consultantAon
Clawback policytrue
Anti-hedgingtrue
Anti-pledgingtrue
06

Say-on-pay — recent advisory votes

Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20262026-06-1847,452,7592,977,290643,62894.1%Passed
20252025-06-2046,450,30212,107,029642,34079.32%Passed
20242024-06-2142,900,39515,499,499402,03473.46%Passed
20222022-06-1640,032,14715,511,1461,437,15272.07%Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

Meeting yearMeeting dateApproval — company's computation
20262026-06-1894.1%a
20252025-06-2079.32%b
20242024-06-2173.46%c

a. Approved under the standard stated in the filing — “Abstentions will have no effect.”.

b. Approved under the standard stated in the filing — “Abstentions will have no effect on the ratification of the appointment of KPMG and the approval of the compensation of our named executive officers.”.

c. Approved under the standard stated in the filing — “Abstentions will have no effect on the ratification of the appointment of KPMG and the approval of the compensation of our named executive officers.”.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

07

CEO pay ratio

Ratio (CEO : median employee)—
CEO total compensation—
Median employee compensation—
08

Director compensation — fiscal year 2025

DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Arthur KirschIndependent · Audit · Compensation · Newly elected$51,092$0$364,241—$0$415,333
Howard BermanIndependent · Nominating and Corporate Governance · Strategy and Public Policy · Newly elected31,6670375,447—0407,114
Jerome AdamsIndependent · Nominating and Corporate Governance · Strategy and Public Policy (Chair)70,00096,20090,702—110,000366,902
Franklin BergerIndependent · Audit · Compensation (Chair)96,00096,20090,702—0282,902
Barbara DuncanIndependent · Audit (Chair) · Nominating and Corporate Governance70,00096,20090,702—0256,902
Polly MurphyIndependent · Nominating and Corporate Governance (Chair) · Strategy and Public Policy65,00096,20090,702—0251,902
Bruce PolskyIndependent · Compensation · Strategy and Public Policy62,50096,20090,702—0249,402
Bruno LucidiIndependent · Audit · Compensation62,50096,20090,702—0249,402
Jean-Pierre SommadossiEmployee director · Board Chair—————0
09

Board fee structure and ownership guideline

Annual cash retainer$45,000
Annual equity retainer—
Per board meeting fee—
Committee chair fees (audit / comp / nom-gov)20,000 / 15,000 / 10,000
Stock ownership guideline—
09b

Total cost of the board

ComponentFY2025
Cash retainers and fees$508,759
Equity awards (grant-date value)$577,200
All other compensation$110,000
Total cost of the board$1,195,959

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

10

Disclosed peer group — fiscal year 2025

The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.

10a

Peer reciprocity

Of the companies Atea Pharmaceuticals, Inc. names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.

Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Atea Pharmaceuticals, Inc..

10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Scholar Rock Holding Corporation2025David Hallal$637,500$22,518,500$7,624,988$452,293$33,300,927
2Vir Biotechnology, Inc.2025Marianne De Backer950,0002,296,8003,507,3601,002,7507,834,045
389bio, Inc.2024Rohan Palekar646,0001,996,0004,623,592337,5357,619,426
4Allakos Inc.2023Robert Alexander805,4602,171,3402,623,519684,6416,299,426
5Anaptys Bio, Inc.2025Daniel Faga706,0111,592,0013,345,653465,9686,133,943
6Replimune Group, Inc.2026Sushil Patel700,0003,376,0031,448,325315,0005,845,982
7Y-mABs Therapeutics, Inc.2024Michael Rossi705,6001,170,7322,288,662392,5964,557,590
8Atea Pharmaceuticals, Inc.2025Jean-Pierre Sommadossi703,4901,315,800962,368422,0943,403,752
9Enanta Pharmaceuticals, Inc.2025Jay Luly803,300128,5501,223,975591,6652,769,548
10Kodiak Sciences Inc.2025Victor Perlroth792,4970923,032772,8242,499,221
11Inozyme Pharma, Inc.2024Douglas Treco541,66701,933,37502,485,392
12Assembly Biosciences, Inc.2025Jason Okazaki647,500661,671573,574585,0002,482,987
13Gossamer Bio, Inc.2025Faheem Hasnain649,64901,392,006254,8002,300,455
14Invivyd, Inc.2025William Duke485,000483,000905,44502,141,222
15Alector, Inc.2025Arnon Rosenthal678,100422,876558,216325,4881,995,018
16Arcturus Therapeutics Holdings, Inc.2025Joseph Payne750,0000941,00001,691,000
17Arbutus Biopharma Corporation2025Lindsay Androski437,7500714,751216,5121,369,013
18Chimerix, Inc.2023Mike Andriole528,47393,135399,282280,5001,312,421
—AlloVir, Inc.——————not in coverage universe

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

10c

Incentive design against the same peers

CompanyAnnual incentive payoutLong-term vehicle mixPSU measures include TSRCompensation consultant
Atea Pharmaceuticals, Inc.not disclosednot disclosednot disclosedAon
89bio, Inc.95%not disclosedNoAon
Alector, Inc.80%not disclosednot disclosedPearl Meyer & Partners, LLC
Allakos Inc.not disclosedOptions 55 · RSU 45NoCompensia
AlloVir, Inc.not disclosedOption 100not disclosedAon plc
Anaptys Bio, Inc.110%not disclosedNoAlpine Rewards
Arbutus Biopharma Corporation110% of target%not disclosednot disclosedRadford (Aon)
Arcturus Therapeutics Holdings, Inc.not disclosedOptions 100not disclosednot disclosed
Assembly Biosciences, Inc.not disclosedOptions 100NoAlpine Rewards, LLC
Chimerix, Inc.85%Option 86 · RSU 14not disclosedAon
Enanta Pharmaceuticals, Inc.not disclosedOptions 80 · PSU 10 · MSU 10NoAlpine Rewards LLC
Gossamer Bio, Inc.65%not disclosedNoAlpine Rewards
Inozyme Pharma, Inc.not disclosednot disclosednot disclosedAlpine Rewards
Invivyd, Inc.132%not disclosednot disclosedAlpine Rewards
Kodiak Sciences Inc.150%Options 100not disclosedCompensia, Inc.
Replimune Group, Inc.not disclosednot disclosedNoPearl Meyer
Scholar Rock Holding Corporationnot disclosednot disclosedNoPay Governance
Vir Biotechnology, Inc.125%Options 67 · RSU 33not disclosedSemler Brossy
Y-mABs Therapeutics, Inc.85.6%not disclosedNoAon

Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.

10d

Frequently asked questions

Who was the highest-paid executive at Atea Pharmaceuticals, Inc. in fiscal 2025?
As disclosed, Jean-Pierre Sommadossi (President, Chief Executive Officer and Chairman of the Board) was the highest-paid executive at Atea Pharmaceuticals, Inc. in fiscal 2025, with total compensation of $3,403,752.
How does Atea Pharmaceuticals, Inc.'s chief executive pay compare to its disclosed peer group?
As disclosed, Jean-Pierre Sommadossi's total compensation ranked at the 59th percentile of Atea Pharmaceuticals, Inc.'s disclosed peer group.
How did shareholders vote on Atea Pharmaceuticals, Inc.'s executive compensation?
As disclosed, 94.1% of shareholders supported Atea Pharmaceuticals, Inc.'s executive compensation in the latest say-on-pay vote.
How much does Atea Pharmaceuticals, Inc. spend in total on board compensation for fiscal 2025?
As disclosed, Atea Pharmaceuticals, Inc. reported total board compensation of $1,195,959 for fiscal 2025.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, Jean-Pierre SommadossiDEF 14A2026-04-270001193125-26-182293Section “Executive Compensation”. As printed: 3,403,752. Filing ↗machine: r3 · c22 · span 1526943–1526952
2Section 01, Janet HammondDEF 14A2026-04-270001193125-26-182293Section “Executive Compensation”. As printed: 1,767,234. Filing ↗machine: r11 · c22 · span 1602448–1602457
3Section 01, Andrea CorcoranDEF 14A2026-04-270001193125-26-182293Section “Executive Compensation”. As printed: 1,690,428. Filing ↗machine: r7 · c22 · span 1564699–1564708
4Section 01, Maria Arantxa HorgaDEF 14A2026-04-270001193125-26-182293Section “Executive Compensation”. As printed: 1,593,827. Filing ↗machine: r15 · c22 · span 1640151–1640160
5Section 01, John VavrickaDEF 14A2026-04-270001193125-26-182293Section “Executive Compensation”. As printed: 1,217,738. Filing ↗machine: r19 · c22 · span 1677840–1677849
6Section 03, Janet Hammond PSUDEF 14A2026-04-270001193125-26-182293Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗
7Section 03, John Vavricka OPTIONDEF 14A2026-04-270001193125-26-182293Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t72 · r7 · c12 · span 1379680–1379687
8Section 03, Andrea Corcoran OPTIONDEF 14A2026-04-270001193125-26-182293Section “NAMED EXECUTIVE OFFICER COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t81 · r7 · c10 · span 1560200–1560207
9Section 03, Jean-Pierre Sommadossi PSUDEF 14A2026-04-270001193125-26-182293Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗
10Section 03, John Vavricka PSUDEF 14A2026-04-270001193125-26-182293Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t72 · r7 · c6 · span 1377168–1377175
11Section 03, Jean-Pierre Sommadossi OPTIONDEF 14A2026-04-270001193125-26-182293Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗
12Section 03, Andrea Corcoran PSUDEF 14A2026-04-270001193125-26-182293Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t72 · r4 · c6 · span 1356497–1356504
13Section 03, Janet Hammond OPTIONDEF 14A2026-04-270001193125-26-182293Section “NAMED EXECUTIVE OFFICER COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t81 · r11 · c10 · span 1597949–1597956
14Section 03, Maria Arantxa Horga PSUDEF 14A2026-04-270001193125-26-182293Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗
15Section 03, Maria Arantxa Horga OPTIONDEF 14A2026-04-270001193125-26-182293Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗
16Section 07, pay ratio10-K2026-03-050001193125-26-094159Section “CEO Pay Ratio”. As printed: —. Filing ↗
17Section 08, Arthur KirschDEF 14A2026-04-270001193125-26-182293Section “Director Compensation”. As printed: 415,333. Filing ↗machine: span 914621–914861
18Section 08, Howard BermanDEF 14A2026-04-270001193125-26-182293Section “Director Compensation”. As printed: 407,114. Filing ↗machine: span 904006–904246
19Section 08, Jerome AdamsDEF 14A2026-04-270001193125-26-182293Section “Director Compensation”. As printed: 366,902. Filing ↗machine: span 893385–893625
20Section 08, Franklin BergerDEF 14A2026-04-270001193125-26-182293Section “Director Compensation”. As printed: 282,902. Filing ↗machine: span 898691–898931
21Section 08, Barbara DuncanDEF 14A2026-04-270001193125-26-182293Section “Director Compensation”. As printed: 256,902. Filing ↗machine: span 909311–909551
22Section 08, Polly MurphyDEF 14A2026-04-270001193125-26-182293Section “Director Compensation”. As printed: 251,902. Filing ↗machine: span 925237–925477
23Section 08, Bruce PolskyDEF 14A2026-04-270001193125-26-182293Section “Director Compensation”. As printed: 249,402. Filing ↗
24Section 08, Bruno LucidiDEF 14A2026-04-270001193125-26-182293Section “Director Compensation”. As printed: 249,402. Filing ↗machine: span 919924–920164
25Section 08, Jean-Pierre SommadossiDEF 14A2026-04-270001193125-26-182293Section “Director Compensation”. As printed: 0. Filing ↗
26Section 02, Polly Murphy 2026-05-18Form 42026-05-210001193125-26-235039Insider equity transaction reported since the proxy statement. Filing ↗
27Section 02, Howard Berman 2026-06-18Form 42026-06-230001193125-26-279723Insider equity transaction reported since the proxy statement. Filing ↗
28Section 02, Bruno Lucidi 2026-06-18Form 42026-06-230001193125-26-279728Insider equity transaction reported since the proxy statement. Filing ↗
29Section 02, Arthur Kirsch 2026-06-18Form 42026-06-230001193125-26-279717Insider equity transaction reported since the proxy statement. Filing ↗
30Section 02, Arthur Kirsch 2026-06-18Form 42026-06-230001193125-26-279717Insider equity transaction reported since the proxy statement. Filing ↗
31Section 02, Jerome Adams 2026-06-18Form 42026-06-230001193125-26-279720Insider equity transaction reported since the proxy statement. Filing ↗
32Section 02, Jerome Adams 2026-06-18Form 42026-06-230001193125-26-279720Insider equity transaction reported since the proxy statement. Filing ↗
33Section 02, Jerome Adams 2026-06-18Form 42026-06-230001193125-26-279720Insider equity transaction reported since the proxy statement. Filing ↗
34Section 02, Jerome Adams 2026-06-18Form 42026-06-230001193125-26-279720Insider equity transaction reported since the proxy statement. Filing ↗
35Section 02, Polly Murphy 2026-06-18Form 42026-06-230001193125-26-279718Insider equity transaction reported since the proxy statement. Filing ↗
36Section 02, Polly Murphy 2026-06-18Form 42026-06-230001193125-26-279718Insider equity transaction reported since the proxy statement. Filing ↗
37Section 02, Polly Murphy 2026-06-18Form 42026-06-230001193125-26-279718Insider equity transaction reported since the proxy statement. Filing ↗
38Section 02, Polly Murphy 2026-06-18Form 42026-06-230001193125-26-279718Insider equity transaction reported since the proxy statement. Filing ↗
39Section 02, Bruce Polsky 2026-06-18Form 42026-06-230001193125-26-279719Insider equity transaction reported since the proxy statement. Filing ↗
40Section 02, Bruce Polsky 2026-06-18Form 42026-06-230001193125-26-279719Insider equity transaction reported since the proxy statement. Filing ↗
41Section 02, Bruce Polsky 2026-06-18Form 42026-06-230001193125-26-279719Insider equity transaction reported since the proxy statement. Filing ↗
42Section 02, Barbara Duncan 2026-06-18Form 42026-06-230001193125-26-279721Insider equity transaction reported since the proxy statement. Filing ↗
43Section 02, Barbara Duncan 2026-06-18Form 42026-06-230001193125-26-279721Insider equity transaction reported since the proxy statement. Filing ↗
44Section 02, Barbara Duncan 2026-06-18Form 42026-06-230001193125-26-279721Insider equity transaction reported since the proxy statement. Filing ↗
45Section 02, Barbara Duncan 2026-06-18Form 42026-06-230001193125-26-279721Insider equity transaction reported since the proxy statement. Filing ↗
46Section 02, Howard Berman 2026-06-18Form 42026-06-230001193125-26-279723Insider equity transaction reported since the proxy statement. Filing ↗
47Section 02, Franklin Berger 2026-06-18Form 42026-06-230001193125-26-279726Insider equity transaction reported since the proxy statement. Filing ↗
48Section 02, Franklin Berger 2026-06-18Form 42026-06-230001193125-26-279726Insider equity transaction reported since the proxy statement. Filing ↗
49Section 02, Franklin Berger 2026-06-18Form 42026-06-230001193125-26-279726Insider equity transaction reported since the proxy statement. Filing ↗
50Section 02, Bruno Lucidi 2026-06-18Form 42026-06-230001193125-26-279728Insider equity transaction reported since the proxy statement. Filing ↗
51Section 02, Bruno Lucidi 2026-06-18Form 42026-06-230001193125-26-279728Insider equity transaction reported since the proxy statement. Filing ↗
52Section 02, Bruno Lucidi 2026-06-18Form 42026-06-230001193125-26-279728Insider equity transaction reported since the proxy statement. Filing ↗
53Section 02, Bruce Polsky 2026-06-18Form 42026-06-230001193125-26-279719Insider equity transaction reported since the proxy statement. Filing ↗
54Section 02, Franklin Berger 2026-06-18Form 42026-06-230001193125-26-279726Insider equity transaction reported since the proxy statement. Filing ↗
55Section 06, 2026 voteForm 8-K2026-06-220001193125-26-277639Item 5.07 · say-on-pay result. As reported: 94.1% (votes for as printed: 47,452,759). Filing ↗
56Section 06, 2025 voteForm 8-K2025-06-200001193125-25-143750Item 5.07 · say-on-pay result. As reported: 79.32% (votes for as printed: 46,450,302). Filing ↗
57Section 06, 2024 voteForm 8-K2024-06-210001193125-24-165886Item 5.07 · say-on-pay result. As reported: 73.46% (votes for as printed: 42,900,395). Filing ↗
58Section 01 trend, Δ column (computed)Computed——Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1)
59Section 03b vehicle mix (computed)Computed——RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio
60Section 09b board cost (computed)Computed——Cash 508,759 + equity 577,200 + all other 110,000 = 1,195,959, summed across the director compensation table rows.machine: formula: Σ = 1,195,959
61Scholar Rock Holding Corporation, Section 10b CEO totalDEF 14A2026-04-220001104659-26-046917CEO total compensation as printed in Scholar Rock Holding Corporation's own proxy. As printed: 33,300,927. Filing ↗machine: r1 · c47 · span 363867–363877
62Vir Biotechnology, Inc., Section 10b CEO totalDEF 14A2026-04-160001628280-26-025379CEO total compensation as printed in Vir Biotechnology, Inc.'s own proxy. As printed: 7,834,045. Filing ↗machine: t71 · r3 · c22 · span 625913–625922
6389bio, Inc., Section 10b CEO totalDEF 14A2025-04-150001193125-25-081504CEO total compensation as printed in 89bio, Inc.'s own proxy. As printed: 7,619,426. Filing ↗machine: span 382144–382153
64Allakos Inc., Section 10b CEO totalDEF 14A2024-04-230000950170-24-047043CEO total compensation as printed in Allakos Inc.'s own proxy. As printed: 6,299,426. Filing ↗machine: r2 · c26 · span 505098–505107
65Anaptys Bio, Inc., Section 10b CEO totalDEF 14A2026-06-290001193125-26-288408CEO total compensation as printed in Anaptys Bio, Inc.'s own proxy. As printed: 6,133,943. Filing ↗machine: span 694406–694415
66Replimune Group, Inc., Section 10b CEO totalDEF 14A2026-07-290001104659-26-087650CEO total compensation as printed in Replimune Group, Inc.'s own proxy. As printed: 5,845,982. Filing ↗machine: r1 · c41 · span 430765–430774
67Y-mABs Therapeutics, Inc., Section 10b CEO totalDEF 14A2025-05-300001558370-25-008299CEO total compensation as printed in Y-mABs Therapeutics, Inc.'s own proxy. As printed: 4,557,590. Filing ↗machine: r5 · c23 · span 597595–597604
68Atea Pharmaceuticals, Inc. (subject), Section 10b CEO totalDEF 14A2026-04-270001193125-26-182293CEO total compensation as printed in Atea Pharmaceuticals, Inc.'s own proxy. As printed: 3,403,752. Filing ↗machine: r3 · c22 · span 1526943–1526952
69Enanta Pharmaceuticals, Inc., Section 10b CEO totalDEF 14A2026-01-260001193125-26-022558CEO total compensation as printed in Enanta Pharmaceuticals, Inc.'s own proxy. As printed: 2,769,548. Filing ↗machine: r2 · c16 · span 830357–830366
70Kodiak Sciences Inc., Section 10b CEO totalDEF 14A2026-04-220001193125-26-170429CEO total compensation as printed in Kodiak Sciences Inc.'s own proxy. As printed: 2,499,221. Filing ↗machine: r4 · c14 · span 905058–905068
71Inozyme Pharma, Inc., Section 10b CEO totalDEF 14A2025-04-290000950170-25-060198CEO total compensation as printed in Inozyme Pharma, Inc.'s own proxy. As printed: 2,485,392. Filing ↗machine: span 345346–345355
72Assembly Biosciences, Inc., Section 10b CEO totalDEF 14A2026-04-220001193125-26-170417CEO total compensation as printed in Assembly Biosciences, Inc.'s own proxy. As printed: 2,482,987. Filing ↗machine: t38 · r2 · c25 · span 1134174–1134183
73Gossamer Bio, Inc., Section 10b CEO totalDEF 14A2026-04-240001728117-26-000027CEO total compensation as printed in Gossamer Bio, Inc.'s own proxy. As printed: 2,300,455. Filing ↗machine: r2 · c48 · span 378559–378568
74Invivyd, Inc., Section 10b CEO totalDEF 14A2026-04-060001193125-26-143783CEO total compensation as printed in Invivyd, Inc.'s own proxy. As printed: 2,141,222. Filing ↗machine: t9 · r2 · c20 · span 501097–501106
75Alector, Inc., Section 10b CEO totalDEF 14A2026-04-280001193125-26-186928CEO total compensation as printed in Alector, Inc.'s own proxy. As printed: 1,995,018. Filing ↗machine: span 1038665–1038674
76Arcturus Therapeutics Holdings, Inc., Section 10b CEO totalDEF 14A2026-04-240001193805-26-000507CEO total compensation as printed in Arcturus Therapeutics Holdings, Inc.'s own proxy. As printed: 1,691,000. Filing ↗machine: t116 · r1 · c27 · span 296910–296919
77Arbutus Biopharma Corporation, Section 10b CEO totalDEF 14A2026-04-140001140361-26-014623CEO total compensation as printed in Arbutus Biopharma Corporation's own proxy. As printed: 1,369,013. Filing ↗machine: r2 · c24 · span 377494–377503
78Chimerix, Inc., Section 10b CEO totalDEF 14A2024-04-260001117480-24-000010CEO total compensation as printed in Chimerix, Inc.'s own proxy. As printed: 1,312,421. Filing ↗
79Section 10a, Assembly Biosciences, Inc. reciprocityDEF 14A—0001193125-26-170417Assembly Biosciences, Inc. names Atea Pharmaceuticals, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗
80Section 10a, 89bio, Inc. reciprocityDEF 14A—0001193125-25-08150489bio, Inc.'s most recent proxy was read; its disclosed peer group does not include Atea Pharmaceuticals, Inc.. Filing ↗
81Section 10a, Arcturus Therapeutics Holdings, Inc. reciprocityDEF 14A—0001193805-26-000507Arcturus Therapeutics Holdings, Inc.'s most recent proxy was read; its disclosed peer group does not include Atea Pharmaceuticals, Inc.. Filing ↗
82Section 10a, Alector, Inc. reciprocityDEF 14A—0001193125-26-186928Alector, Inc.'s most recent proxy was read; its disclosed peer group does not include Atea Pharmaceuticals, Inc.. Filing ↗
83Section 10a, Allakos Inc. reciprocityDEF 14A—0000950170-24-047043Allakos Inc.'s most recent proxy was read; its disclosed peer group does not include Atea Pharmaceuticals, Inc.. Filing ↗
84Section 10a, Chimerix, Inc. reciprocityDEF 14A—0001117480-24-000010Chimerix, Inc.'s most recent proxy was read; its disclosed peer group does not include Atea Pharmaceuticals, Inc.. Filing ↗
85Section 10a, Enanta Pharmaceuticals, Inc. reciprocityDEF 14A—0001193125-26-022558Enanta Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include Atea Pharmaceuticals, Inc.. Filing ↗
86Section 10a, Anaptys Bio, Inc. reciprocityDEF 14A—0001193125-26-288408Anaptys Bio, Inc.'s most recent proxy was read; its disclosed peer group does not include Atea Pharmaceuticals, Inc.. Filing ↗
87Section 10a, Y-mABs Therapeutics, Inc. reciprocityDEF 14A—0001558370-25-008299Y-mABs Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Atea Pharmaceuticals, Inc.. Filing ↗
88Section 10a, Gossamer Bio, Inc. reciprocityDEF 14A—0001728117-26-000027Gossamer Bio, Inc. names Atea Pharmaceuticals, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗
89Section 10a, Vir Biotechnology, Inc. reciprocityDEF 14A—0001628280-26-025379Vir Biotechnology, Inc.'s most recent proxy was read; its disclosed peer group does not include Atea Pharmaceuticals, Inc.. Filing ↗
90Section 10a, Scholar Rock Holding Corporation reciprocityDEF 14A—0001104659-26-046917Scholar Rock Holding Corporation's most recent proxy was read; its disclosed peer group does not include Atea Pharmaceuticals, Inc.. Filing ↗
91Section 10a, Kodiak Sciences Inc. reciprocityDEF 14A—0001193125-26-170429Kodiak Sciences Inc.'s most recent proxy was read; its disclosed peer group does not include Atea Pharmaceuticals, Inc.. Filing ↗

The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.

You'll confirm on The Pay Desk's sign-up page.

Get the Atea Pharmaceuticals, Inc. Executive Compensation Report

$1,500

Buy the report - $1,500Both reports - $2,400
AVIR Peer Teardown Report